Hims & Hers Health, Inc. (NYSE:HIMS – Get Rating) insider Irene Becklund sold 11,002 shares of Hims & Hers Health stock in a transaction on Friday, September 9th. The shares were sold at an average price of $6.64, for a total transaction of $73,053.28. Following the completion of the sale, the insider now owns 2,715 shares in the company, valued at approximately $18,027.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Irene Becklund also recently made the following trade(s):

• On Tuesday, July 5th, Irene Becklund sold 19,331 shares of Hims & Hers Health stock. The shares were sold at an average price of $5.00, for a total transaction of $96,655.00.

Hims & Hers Health Stock Down 0.6 %

NYSE HIMS opened at $6.64 on Tuesday. Hims & Hers Health, Inc. has a 52 week low of $2.72 and a 52 week high of $9.35. The firm has a market capitalization of $1.36 billion, a P/E ratio of -16.19 and a beta of 0.46. The company has a 50-day moving average price of $6.14 and a 200-day moving average price of $5.05.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on HIMS. Guggenheim boosted their target price on shares of Hims & Hers Health to $12.00 in a report on Monday, August 15th. Deutsche Bank Aktiengesellschaft boosted their target price on shares of Hims & Hers Health from $7.00 to $8.00 in a report on Wednesday, August 10th. SVB Leerink upped their price target on shares of Hims & Hers Health from $4.00 to $5.00 and gave the stock an "underperform" rating in a research note on Tuesday, August 9th. Truist Financial assumed coverage on shares of Hims & Hers Health in a research note on Wednesday, September 7th. They issued a "hold" rating and a $7.00 price target on the stock. Finally, Piper Sandler dropped their price target on shares of Hims & Hers Health from $8.00 to $6.00 and set an "overweight" rating on the stock in a research note on Thursday, May 26th. One analyst has rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating to the stock. According to MarketBeat, Hims & Hers Health currently has a consensus rating of "Hold" and an average target price of $7.38.

Institutional Investors Weigh In On Hims & Hers Health

Hedge funds and other institutional investors have recently made changes to their positions in the business. Teacher Retirement System of Texas grew its stake in shares of Hims & Hers Health by 25.6% during the 4th quarter. Teacher Retirement System of Texas now owns 14,808 shares of the company's stock valued at $97,000 after acquiring an additional 3,022 shares during the period. Northern Trust Corp grew its stake in shares of Hims & Hers Health by 1.3% during the 1st quarter. Northern Trust Corp now owns 253,307 shares of the company's stock valued at $1,350,000 after acquiring an additional 3,226 shares during the period. HighTower Advisors LLC grew its stake in shares of Hims & Hers Health by 14.4% during the 4th quarter. HighTower Advisors LLC now owns 31,761 shares of the company's stock valued at $209,000 after acquiring an additional 3,998 shares during the period. Royal Bank of Canada grew its stake in shares of Hims & Hers Health by 18.4% during the 1st quarter. Royal Bank of Canada now owns 26,523 shares of the company's stock valued at $140,000 after acquiring an additional 4,126 shares during the period. Finally, Baldwin Brothers LLC MA grew its stake in shares of Hims & Hers Health by 21.5% during the 1st quarter. Baldwin Brothers LLC MA now owns 27,605 shares of the company's stock valued at $147,000 after acquiring an additional 4,889 shares during the period. Hedge funds and other institutional investors own 43.41% of the company's stock.

About Hims & Hers Health

(Get Rating)

Hims & Hers Health, Inc operates a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products, primarily focusing on wellness, sexual health and wellness, skincare, and hair care.

Featured Articles

• Get a free copy of the StockNews.com research report on Hims & Hers Health (HIMS)
• Do These Dividend Achievers Deserve A Place In Your Portfolio?
• Darden Restaurants Takes the Low Road Against Inflation
• Why These 3 Stocks Are Off to Hot September Starts
• Inflation Doesn't Differentiate, But it's Impact Does
• 3 Downgraded Must-Have Stocks To Put On Your Watchlist

Receive News & Ratings for Hims & Hers Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hims & Hers Health and related companies with MarketBeat.com's FREE daily email newsletter.